Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Phase 2 Completed 36 enrolled University Health Network, Toronto Pfizer · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

Timeline

Start: 2006-09-25
Primary completion: 2016-09-19
Completion: 2016-09-19

Publications

Background Horgan AM, Darling G, Wong R, Guindi M, Liu G, Jonker DJ, Lister J, Xu W, MacKay HM, Dinniwell R, Kim J, Pierre A, Shargall Y, Asmis TR, Agboola O, Seely AJ, Ringash J, Wells J, Marginean EC, Haider M, Knox JJ. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial. Dis Esophagus. 2016 Nov;29(8):1152-1158. doi: 10.1111/dote.12444. Epub 2015 Dec 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	12.5 mg	Oral
Subject	Sunitinib	Small molecule	50 mg	Oral
Background	Cisplatin	Other / unclassified	65 mg/m2	—
Background	Irinotecan	Small molecule	50 mg/m2	—

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Summary

Timeline

Publications

Drugs

Indications